Office Management of COPD in Primary Care: A 2009 Clinical Update

References

• . Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932–946
   PubMed Web of Science ®Google Scholar
• . O'Donnell DE, Hernandez P, Kaplan A, . Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease—2008 update—highlights for primary care. Can Respir J. 2008;15( suppl A):1A–8A
   PubMed Web of Science ®Google Scholar
• . U.S. Preventive Services Task Force. Screening for chronic obstructive pulmonary disease using spirometry: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;148(7):529–534
   PubMed Web of Science ®Google Scholar
• . Global Strategy for the Diagnosis, Management, and Prevention of COPD (Updated 2008). Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD). http://www.goldcopd.com. Accessed 24 June, 2009
   Google Scholar
• . Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977;1(6077):1645–1648
   PubMed Web of Science ®Google Scholar
• . Lundbäck B, Lindberg A, Lindström M, ; Obstructive Lung Disease in Northern Sweden Studies. Not 15 but 50% of smokers develop COPD?—Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med. 2003;97(2):115–122
   PubMed Web of Science ®Google Scholar
• . Chen Y, Breithaupt K, Muhajarine N. Occurrence of chronic obstructive pulmonary disease among Canadians and sex-related risk factors. J Clin Epidemiol. 2000;53(7):755–761
   PubMed Web of Science ®Google Scholar
• . Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance—United States, 1971-2000. MMWR Surveill Summ. 2002;51(6):1–16
   Google Scholar
• . Centers for Disease Control (CDC). Smoking and health: a national status report. MMWR Morb Mortal Wkly Rep. 1986;35(46):709–711
   PubMedGoogle Scholar
• . Vonk JM, Jongepier H, Panhuysen CI, Schouten JP, Bleecker ER, Postma DS. Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up. Thorax. 2003;58(4):322–327
   PubMed Web of Science ®Google Scholar
• . Mosenifar Z. Differentiating COPD from asthma in clinical practice. Postgrad Med. 2009;121(3):105–112
   PubMed Web of Science ®Google Scholar
• . Martinez FJ, Raczek AE, Seifer FD, ; COPD-PS Clinician Working Group. Development and initial validation of a self-scored COPD Population Screener Questionnaire (COPD-PS). COPD. 2008;5(2):85–95
   PubMedGoogle Scholar
• . Price DB, Tinkelman DG, Halbert RJ, . Symptom-based questionnaire for identifying COPD in smokers. Respiration. 2006;73(3):285–295
   PubMed Web of Science ®Google Scholar
• . Tinkelman DG, Price DB, Nordyke RJ, . Symptom-based questionnaire for differentiating COPD from asthma. Respiration. 2006;73(3):296–305
   PubMed Web of Science ®Google Scholar
• . Tinkelman DG, Price DB, Nordyke RJ, Halbert RJ. Misdiagnosis of COPD and asthma in primary care patients 40 years of age and over. J Asthma. 2006;43(1):75–80
   PubMed Web of Science ®Google Scholar
• . Calverley PM, Anderson JA, Celli, B, ; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Eng J Med. 2007;356(8):775–789
   PubMed Web of Science ®Google Scholar
• . Parkes G, Greenhalgh T, Griffin M, Dent R. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ. 2008;336(7644):598–600
   PubMedGoogle Scholar
• . Fletcher CM, Elmes PC, Fairbairn AS, Wood CH. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J. 1959;2(5147):257–266
   PubMed Web of Science ®Google Scholar
• . A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. The Tobacco Use and Dependence Clinical Practice Guideline Panel, Staff, and Consortium Representatives. JAMA. 2000;283(24):3244–3254
   PubMed Web of Science ®Google Scholar
• . Tashkin D, Kanner R, Bailey W, . Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomized trial. Lancet. 2001;357(9268): 1571–1575
   PubMed Web of Science ®Google Scholar
• . Wagena EJ, Knipschild PG, Huibers MJ, Wouters EF, van Schayck CP. Efficacy of bupropion and notriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease. Arch Intern Med. 2005;165(19):2286–2292
   PubMedGoogle Scholar
• . Gonzales D, Rennard SI, Nides M, ; Varenicline Phase 3 Study Group. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):47–55
   PubMed Web of Science ®Google Scholar
• . Jorenby DE, Hays JT, Rigotti NA, ; Varenicline Phase 3 Study Group. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56–63
   PubMed Web of Science ®Google Scholar
• . Tonstad S, Tønnesen P, Hajek P, Williams KE, Billing CB, Reeves KR; Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296(1):64–71
   PubMed Web of Science ®Google Scholar
• . Nides M, Oncken C, Gonzales D, . Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med. 2006;166(15):1561–1568
   PubMed Web of Science ®Google Scholar
• . Williams KE, Reeves KR, Billing CB Jr, Pennington AM, Gong J. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin. 2007;23(4):793–801
   PubMed Web of Science ®Google Scholar
• . Tsai ST, Cho HJ, Cheng HS, . A randomized, placebo-controlled trial of varenicline, a selective alpha4bta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther. 2007;29(6):1027–1039
   PubMed Web of Science ®Google Scholar
• . Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves KR. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther. 2007;29(6):1040–1056
   PubMed Web of Science ®Google Scholar
• . Nides M, Glover ED, Reus VI, . Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. Am J Health Behav. 2008;32(6):664–675
   PubMed Web of Science ®Google Scholar
• . Aubin HJ, Bobak A, Britton JR, . Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomized open-label trial. Thorax. 2008;63(8):717–724
   PubMed Web of Science ®Google Scholar
• . Radin A, Cote C. Primary care of the patient with chronic obstructive pulmonary disease-part 1: frontline prevention and early diagnosis. Am J Med. 2008;121( 7 suppl):S3–S12
   PubMed Web of Science ®Google Scholar
• . Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med. 2009;169(3):219–229
   PubMed Web of Science ®Google Scholar